Current in-house programmes are focussed on auto-immune anti-inflammatory conditions where current first-line steroid and systemic biologics are failing to deliver the required medical outcomes for all patients.
Using the inherent qualities of their small size, stable nature and unique neutralisation potencies, Elasmogen is developing site-specific soloMERs that can deliver rapid alleviation of disease, minimise systemic exposure and side-effects and offer the promise of self-administered, longer-term treatments.
ELN/21 and ELN/22
Uveitis ranks fifth in the causes of blindness in the developed world, and is believed to be responsible for 10% of cases of visual loss in the age group of 20–60 years. The auto-immune form of this disease is characterised by a rapid and debilitating inflammation of the uvea. This is a condition that requires immediate treatment to prevent partial or total and irreversible loss of sight. The current first-line therapies are corticosteroids, but at least one third of patients fail to respond to this form of “sledge-hammer” immunomodulation with many more suffering side-effects to the steroids themselves (glaucoma and cataracts).
ELN/21 and 22 show the potential to be potent and sight-saving medicines for the treatment of this corticosteroid-refractive, patient population. Recognising validated targets, topical or site-specific delivery of soloMERs will provide immediate therapy at the point of need, limit systemic exposure and have the potential to become a patient-administered, longer term therapy for this debilitating condition.
Elasmogen has related site-specific, soloMER programmes looking to improve patient outcomes in Dry Eye, Corneal Graft Rejection and in sub-sets of patients suffering from Irritable Bowel and Crone’s Disease.